Ventyx biosciences announces closing of upsized initial public offering and full exercise of underwriters' option to purchase additional shares

Encinitas, calif., oct. 25, 2021 (globe newswire) -- ventyx biosciences, inc. (nasdaq: vtyx), a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune disorders, announced today the closing of its upsized initial public offering of 10,893,554 shares of its common stock, which includes the full exercise of the underwriters' option to purchase 1,420,898 additional shares, at an initial public offering price of $16.00 per share. the aggregate gross proceeds from the offering were approximately $174.3 million, before deducting underwriting discounts and commissions and offering expenses payable by ventyx. all shares in the offering were offered by ventyx and began trading on the nasdaq global select market on october 21, 2021 under the ticker symbol “vtyx.”
VTYX Ratings Summary
VTYX Quant Ranking